NEW YORK (GenomeWeb News) – Fluidigm said that it could receive up to an additional $3.2 million in proceeds from its minority stake in Verinata, acquired by Illumina in February for up to $450 million. In March Fluidigm received proceeds of $3.1 million in exchange for its ownership in Verinata, resulting in a gain of $1.8 million, it said in its Form 10-Q filed this week. Fluidigm added that it could receive the additional $3.2 million in proceeds if "certain milestone payments become payable."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.